Regenerative Patch Technologies LLC (RPT) is a California company developing a stem cell-based implant technology for the treatment of retinal diseases. CPCB-RPE1 is RPT’s lead product which is in clinical development in patients with geographic atrophy. CPCB-RPE1 consists of pluripotent stem cell derived polarized retinal pigmented epithelial cells on an ultrathin parylene membrane which mimics the diffusion characteristics of the Bruch’s membrane.

RPT was founded by Drs. Mark Humayun and David R. Hinton from the University of Southern California and Dr. Dennis O. Clegg from UC Santa Barbara. The technology to produce the CPCB-RPE1 implant is exclusively licensed to RPT from the University of Southern California, the California Institute of Technology and UC at Santa Barbara.

Contact Regenerative Patch Technologies
inquiries@regenerativepatch.com
Visit Website